The solution darkens when mixed with certain medications
Em um ato que reflete a vigilância constante sobre a cadeia farmacêutica, a Anvisa interveio para proteger pacientes brasileiros de medicamentos com defeitos de qualidade e produtos herbais sem registro sanitário. Dois grandes fabricantes — Hypofarma e Cimed — tiveram lotes suspensos por falhas que vão da instabilidade química à troca de embalagens, enquanto dezenas de compostos fitoterápicos clandestinos foram banidos do mercado. A ação lembra que a confiança depositada em um medicamento começa muito antes do momento em que ele chega às mãos do paciente.
- Um lote de injeção de dexametasona da Hypofarma escurece ao ser misturado com outros fármacos — sinal de instabilidade química que pode comprometer o tratamento de pacientes inflamados.
- Na Cimed, caixas rotuladas como Atorvastatina 40 mg continham cartuchos de Rosuvastatina 20 mg, colocando pacientes em risco de tomar o medicamento errado sem saber.
- Mais de uma dúzia de compostos herbais e fitoterápicos sem registro sanitário — prometendo curar diabetes, psoríase e dependência de tabaco — foram proibidos de circular no país.
- A Anvisa agiu com suspensão imediata de distribuição e venda, exigindo que varejistas retirem os produtos e que consumidores verifiquem os números de lote antes de qualquer uso.
- O episódio expõe a tensão permanente entre o mercado de remédios tradicionais e a regulação sanitária moderna, reforçando que produtos sem aprovação oficial operam fora de qualquer garantia de segurança.
Na segunda-feira, a Anvisa suspendeu a venda e distribuição de lotes específicos de medicamentos de dois grandes fabricantes brasileiros, após identificar problemas de qualidade com potencial risco à saúde dos pacientes.
A Hypofarma iniciou um recall voluntário do lote 25091566 de sua injeção de fosfato de dexametasona, um corticosteroide amplamente usado no controle de inflamações. O problema: a solução apresenta escurecimento quando combinada com certos outros medicamentos, indicando instabilidade química que pode afetar tanto a eficácia quanto a segurança do produto. O lote, comercializado em caixas com 50 frascos injetáveis a 4 mg/mL, está proibido de circular até que a questão seja completamente resolvida.
Já a Cimed enfrentou um problema de natureza diferente, mas igualmente grave. O lote 2424299 de seus medicamentos para colesterol apresentou troca de embalagens: caixas identificadas como Atorvastatina 40 mg continham, na verdade, cartuchos de Rosuvastatina 20 mg. Embora ambos tratem o colesterol elevado, atuam por mecanismos distintos e possuem posologias diferentes — um paciente que tome o produto errado sem perceber pode sofrer consequências sérias à saúde. A Anvisa suspendeu os dois produtos associados ao lote.
Além dos recalls farmacêuticos, a agência proibiu a fabricação, venda, importação e publicidade de mais de uma dúzia de compostos herbais e fitoterápicos sem registro sanitário. Entre eles, produtos com nomes que prometem soluções abrangentes — Composto Cura Tudo, Composto para Diabetes, Composto para Cessação do Tabagismo — e toda a linha da marca Status Verde, incluindo formulações minerais e herbais diversas.
A ação reforça um alerta recorrente: sem registro sanitário, esses produtos não passaram pelos testes e controles de qualidade exigidos para garantir segurança e eficácia. Consumidores que adquiriram qualquer um dos itens listados devem suspender o uso imediatamente, e varejistas são obrigados a retirá-los do estoque. O episódio ilustra o desafio contínuo de equilibrar a tradição da medicina herbal com as exigências da regulação sanitária moderna.
Brazil's health regulator moved swiftly on Monday to pull multiple medications from shelves after discovering quality problems that could affect patient safety. The Agência Nacional de Vigilância Sanitária, known as Anvisa, suspended the sale and distribution of specific drug batches from two major manufacturers—Hypofarma and Cimed—citing defects serious enough to warrant immediate action.
Hypofarma initiated a voluntary recall of batch 25091566 of its dexamethasone phosphate injection, a corticosteroid commonly used to reduce inflammation. The company discovered that the solution darkens when mixed with certain other medications, a sign of chemical instability that could compromise the drug's effectiveness or safety. The affected product comes in boxes of 50 injectable vials at a concentration of 4 milligrams per milliliter. Anvisa's suspension prevents any further distribution or use of this batch until the issue is fully resolved.
Cimed, another major pharmaceutical manufacturer, reported a different but equally concerning problem with its cholesterol medications. The company found that batch 2424299 contained a packaging mix-up: boxes labeled as Atorvastatin 40 milligrams contained cartridges of Rosuvastatin 20 milligrams instead. Both drugs treat high cholesterol but work through different mechanisms and carry different dosing instructions. A patient taking the wrong medication without realizing it could face serious health consequences. Anvisa suspended both the Atorvastatin and Rosuvastatin products associated with this batch.
Beyond the branded pharmaceutical recalls, Anvisa took broader action against unregistered herbal products flooding the Brazilian market. The agency issued an outright ban on the manufacture, sale, distribution, importation, and advertising of more than a dozen herbal compounds and phytotherapeutics that lack proper sanitary registration, notification, or licensing. These products carry names that promise cure-all benefits: Compound Cure Everything, Compound for Diabetes, Compound for Psoriasis, Compound for Smoking Cessation, and others with similarly expansive claims. The agency also targeted all batches of products sold under the Status Verde brand, including Compound Anti-Diabetes, Valerian Compound, and several mineral and herbal formulations.
The regulatory action reflects a broader concern about unregistered remedies circulating in Brazil's health market. Without proper sanitary registration, these products have not undergone the testing and quality controls required to ensure they are safe and effective. Consumers who purchased any of these items are now prohibited from using them, and retailers must remove them from inventory. The suspensions and bans underscore the ongoing tension between traditional herbal medicine practices and modern pharmaceutical regulation—a balance Brazil's health authorities are attempting to strike by allowing registered herbal products while cracking down on those operating outside the regulatory framework.
Citas Notables
Hypofarma identified darkening of the solution when the product is diluted in combination with certain medications— Hypofarma (voluntary recall notification)
Cimed reported suspected mixing of packaging with Rosuvastatin cartridges identified in an Atorvastatin batch— Cimed (voluntary recall notification)
La Conversación del Hearth Otra perspectiva de la historia
Why does a corticosteroid injection turning dark when mixed with other drugs matter so much that it requires a full suspension?
Because that discoloration signals a chemical reaction—the drug is breaking down or changing in ways we don't fully understand. A patient receiving that injection might get less of the active ingredient, or something harmful instead. You can't see it happening inside the body.
And the cholesterol medication mix-up—how does that even happen at a major manufacturer?
Packaging errors at scale. Thousands of boxes moving through a facility. Someone catches it, which is good, but only after some boxes have already shipped. A patient taking the wrong cholesterol drug for weeks wouldn't necessarily feel it immediately.
What about these herbal products with names like "Cure Everything"? Are they actually dangerous, or just unproven?
Both. Unproven means we don't know if they work. But unregistered means we also don't know what's actually in them, how much, or if it's contaminated. That's the real danger—the unknown.
So Anvisa is saying these herbal products shouldn't exist at all?
Not exactly. Herbal medicine is legal in Brazil if it's registered and tested. What Anvisa banned are the ones operating in the shadows, making big promises without any oversight.
Who bears the cost if someone was already taking one of these banned products?
The patient does, mostly. They have to stop taking something they believed was helping them, and they have no recourse if it caused harm. That's why the agency moves fast—to minimize how many people are exposed.